.

Make Better Decisions

  • Analyze global market entry opportunities
  • Uncover prior art in expired and abandoned patents
  • Obtain formulation and manufacturing information

► See Plans & Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving 500+ biopharmaceutical companies globally:

Moodys
US Army
Fuji
Queensland Health
McKesson
Federal Trade Commission
Medtronic
Harvard Business School
Deloitte
Colorcon

Generated: September 24, 2017

DrugPatentWatch Database Preview

Details for New Drug Application (NDA): 205834

« Back to Dashboard
NDA 205834 describes HARVONI, which is a drug marketed by Gilead Sciences Inc and is included in one NDA. It is available from one supplier. There are fifteen patents protecting this drug. Additional details are available on the HARVONI profile page.

The generic ingredient in HARVONI is ledipasvir; sofosbuvir. One supplier is listed for this compound. Additional details are available on the ledipasvir; sofosbuvir profile page.

Summary for NDA: 205834

Tradename:
1
Applicant:
1
Ingredient:
1
Patents:15
Formulation / Manufacturing:see details

Suppliers and Packaging for NDA: 205834

Tradename Generic Name Dosage NDA Application Type Supplier National Drug Code Package Code Package
HARVONI
ledipasvir; sofosbuvir
TABLET;ORAL 205834 NDA Gilead Sciences, Inc 61958-1801 61958-1801-1 28 TABLET, FILM COATED in 1 BOTTLE, PLASTIC (61958-1801-1)

Summary for product number 001

Active Rx/OTC/Discontinued:RXDosage:TABLET;ORALStrength90MG;400MG
Approval Date:Oct 10, 2014TE:RLD:Yes
Regulatory Exclusivity Expiration:Nov 12, 2018
Regulatory Exclusivity Use:EXPANDED INDICATION TO INCLUDE SUBJECTS INFECTED WITH CHRONIC HEPATITIS C, GENOTYPE 6 VIRUS INFECTION BASED UPON THE RESULTS OF THE ELECTRON- 2 STUDY
Regulatory Exclusivity Expiration:Nov 12, 2018
Regulatory Exclusivity Use:EXPANDED INDICATION TO INCLUDE THE TREATMENT OF SUBJECTS WITH GENOTYPE 5 CHRONIC HEPATITIS C VIRUS INFECTION BASED ON THE RESULTS FROM STUDY GS-US-337-119.
Regulatory Exclusivity Expiration:Nov 12, 2018
Regulatory Exclusivity Use:EXPANDED INDICATION TO INCLUDE TREATMENT OF GENOTYPE 4, CHRONIC HEPATITIS C VIRUS INFECTION BASED UPON THE RESULTS FROM STUDIES ION-4 AND GS-US-337-119.


Complete Access Available with Subscription
« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

Serving 500+ biopharmaceutical companies globally:

Dow
Teva
Deloitte
Moodys
Express Scripts
Fuji
Healthtrust
McKesson
US Department of Justice
Cerilliant

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted Heap | Mobile and Web Analytics
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:



Google
Twitter
Google Plus
botpot